Spero Therapeutics, Inc. entered into a license agreement with Innovent Biologics to develop and commercialize a CD40L monoclonal antibody, involving a $35.0 million upfront payment and up to $1.05 billion in milestone payments. Additionally, the company secured royalty financing through a $105.0 million senior secured note purchase and a royalty interest purchase, which is expected to extend its cash runway into the second half of 2029. Spero Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for infectious diseases and inflammatory conditions.
